Cargando…

Exploring the role of drug-metabolising enzymes in antidepressant side effects

RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P45...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodgson, Karen, Tansey, Katherine E., Uher, Rudolf, Dernovšek, Mojca Zvezdana, Mors, Ole, Hauser, Joanna, Souery, Daniel, Maier, Wolfgang, Henigsberg, Neven, Rietschel, Marcella, Placentino, Anna, Craig, Ian W., Aitchison, Katherine J., Farmer, Anne E., Dobson, Richard J. B., McGuffin, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480333/
https://www.ncbi.nlm.nih.gov/pubmed/25761838
http://dx.doi.org/10.1007/s00213-015-3898-x
_version_ 1782378144802537472
author Hodgson, Karen
Tansey, Katherine E.
Uher, Rudolf
Dernovšek, Mojca Zvezdana
Mors, Ole
Hauser, Joanna
Souery, Daniel
Maier, Wolfgang
Henigsberg, Neven
Rietschel, Marcella
Placentino, Anna
Craig, Ian W.
Aitchison, Katherine J.
Farmer, Anne E.
Dobson, Richard J. B.
McGuffin, Peter
author_facet Hodgson, Karen
Tansey, Katherine E.
Uher, Rudolf
Dernovšek, Mojca Zvezdana
Mors, Ole
Hauser, Joanna
Souery, Daniel
Maier, Wolfgang
Henigsberg, Neven
Rietschel, Marcella
Placentino, Anna
Craig, Ian W.
Aitchison, Katherine J.
Farmer, Anne E.
Dobson, Richard J. B.
McGuffin, Peter
author_sort Hodgson, Karen
collection PubMed
description RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive. OBJECTIVES: We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline. METHODS: Patients were genotyped for the enzymes CYP2C19 and CYP2D6, and serum concentrations of both antidepressant and primary metabolite were measured after 8 weeks of treatment. Side effects were assessed weekly. We investigated associations between P450 genotypes, serum concentrations of antidepressants and side effects, as well as the relationship between P450 genotype and study discontinuation. RESULTS: P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0.5638, β = −0.133, standard error (SE) = 0.229; escitalopram: n = 340, p = 0.9627, β = −0.004, SE = 0.085), study discontinuation (nortriptyline n = 284, hazard ratio (HR) = 1.300, p = 0.174; escitalopram n = 376, HR = 0.870, p = 0.118) or specific side effects. Serum concentrations of antidepressant were only related to a minority of the specific side effects measured: dry mouth, dizziness and diarrhoea. CONCLUSIONS: In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants. Serum drug concentrations appear to only explain variability in the occurrence of a minority of specific side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3898-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4480333
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44803332015-07-01 Exploring the role of drug-metabolising enzymes in antidepressant side effects Hodgson, Karen Tansey, Katherine E. Uher, Rudolf Dernovšek, Mojca Zvezdana Mors, Ole Hauser, Joanna Souery, Daniel Maier, Wolfgang Henigsberg, Neven Rietschel, Marcella Placentino, Anna Craig, Ian W. Aitchison, Katherine J. Farmer, Anne E. Dobson, Richard J. B. McGuffin, Peter Psychopharmacology (Berl) Original Investigation RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive. OBJECTIVES: We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline. METHODS: Patients were genotyped for the enzymes CYP2C19 and CYP2D6, and serum concentrations of both antidepressant and primary metabolite were measured after 8 weeks of treatment. Side effects were assessed weekly. We investigated associations between P450 genotypes, serum concentrations of antidepressants and side effects, as well as the relationship between P450 genotype and study discontinuation. RESULTS: P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0.5638, β = −0.133, standard error (SE) = 0.229; escitalopram: n = 340, p = 0.9627, β = −0.004, SE = 0.085), study discontinuation (nortriptyline n = 284, hazard ratio (HR) = 1.300, p = 0.174; escitalopram n = 376, HR = 0.870, p = 0.118) or specific side effects. Serum concentrations of antidepressant were only related to a minority of the specific side effects measured: dry mouth, dizziness and diarrhoea. CONCLUSIONS: In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants. Serum drug concentrations appear to only explain variability in the occurrence of a minority of specific side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3898-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-03-12 2015 /pmc/articles/PMC4480333/ /pubmed/25761838 http://dx.doi.org/10.1007/s00213-015-3898-x Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Investigation
Hodgson, Karen
Tansey, Katherine E.
Uher, Rudolf
Dernovšek, Mojca Zvezdana
Mors, Ole
Hauser, Joanna
Souery, Daniel
Maier, Wolfgang
Henigsberg, Neven
Rietschel, Marcella
Placentino, Anna
Craig, Ian W.
Aitchison, Katherine J.
Farmer, Anne E.
Dobson, Richard J. B.
McGuffin, Peter
Exploring the role of drug-metabolising enzymes in antidepressant side effects
title Exploring the role of drug-metabolising enzymes in antidepressant side effects
title_full Exploring the role of drug-metabolising enzymes in antidepressant side effects
title_fullStr Exploring the role of drug-metabolising enzymes in antidepressant side effects
title_full_unstemmed Exploring the role of drug-metabolising enzymes in antidepressant side effects
title_short Exploring the role of drug-metabolising enzymes in antidepressant side effects
title_sort exploring the role of drug-metabolising enzymes in antidepressant side effects
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480333/
https://www.ncbi.nlm.nih.gov/pubmed/25761838
http://dx.doi.org/10.1007/s00213-015-3898-x
work_keys_str_mv AT hodgsonkaren exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT tanseykatherinee exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT uherrudolf exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT dernovsekmojcazvezdana exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT morsole exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT hauserjoanna exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT souerydaniel exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT maierwolfgang exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT henigsbergneven exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT rietschelmarcella exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT placentinoanna exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT craigianw exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT aitchisonkatherinej exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT farmerannee exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT dobsonrichardjb exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects
AT mcguffinpeter exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects